UCB 30
Type of financial instrument
Corporate Bond
Sub-Type
Technology
Yield
3.88
Yield spread Bundesanleihe
1.0555
Tradable for private investors
No
Minimum amount tradeable unit
100,000.00
Maturity
20/03/2030
Interest Rate
4.25 %
Currency
Euro
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE / YIELD | 101.266 G / 3.88 | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 09:47:50 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 1.0555 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 101.338 | 101.22 |
| PREV. DAY'S PRICE | 101.354 | (07/21) |
| CHANGE DAY BEFORE | -0.09 | -0.09 % |
| 52 WEEK HIGH / LOW | 104.113 (10/16) | 101.159 (03/27) |
Master Data
| WKN | A3LWC4 |
| ISIN | BE0390119825 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Technology |
| ISSUER | UCB S.A. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 4.25 % |
| INTEREST RUN FROM | 20/03/2024 |
| NEXT INTEREST PAYMENT | 20/03/2027 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 1.49 % |
| TRADING CURRENCY / NOTATION | Euro/ Percent |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 500.00 Mil. |
| MINIMUM AMOUNT TRADEABLE UNIT | 100,000.00 |
| SMALLEST TRADEABLE UNIT | 100,000.00 |
| MATURITY | 20/03/2030 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | Yes |
| BOND IS SUBORDINATED | No |
Description
Make Whole Call Option. Callable bond.
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.